medical marijuana industry
Public opinion surveys find most Americans support legalization of medical marijuana, even as they reject broader legalization of the drug. A Gallup survey found 75% said they would favor use of marijuana under a doctor's prescription, but nearly two-thirds rejected full legalization. While Congress has consistently rejected legislation to allow medical use of marijuana, 33 states and the District of Columbia have authorized it in some form. Most require that it be "prescribed", which is problematic when federal agencies control doctors' power to prescribe. Many states have made laws which permit doctors to instead "recommend" marijuana, starting with California Proposition 215 (1996).
AlleyBioSystems,LLC owns Trademarks / Copyrights or Domain Names related to the medical marijuana industry. Cannabidiol (CBD) is one of at least 85 cannabinoids found in cannabis and is considered to have a wide scope of medical applications. CBD is in Schedule I in the United States. It is included in the DEA material under "Tetrahydrocannabinols," which is a broad category that encompasses all the phytocannabinoids as analogs of THC. Its DEA # is 7372, and it remains illegal .
The issue before Congress is whether to continue the federal prosecution of medical marijuana patients and their providers, in accordance with the federal Controlled Substances Act (CSA), or whether to relax federal marijuana prohibition enough to permit the medicinal use of botanical cannabis products when recommended by a physician, especially where permitted under state law. Sixteen states, mostly in the West, have enacted laws allowing the use of marijuana for medical purposes, and many thousands of patients are seeking relief from a variety of serious illnesses by smoking marijuana or using other herbal cannabis preparations. Two bills relating to the therapeutic use of cannabis have been introduced in the 111th Congress. The Medical Marijuana Patient Protection Act (H.R. 2835), which would allow the medical use of marijuana in states that permit its use with a doctor's recommendation, was introduced on June 11, 2009, by Representative Barney Frank. The bill would move marijuana from Schedule I to Schedule II of the CSA and exempt from federal prosecution authorized patients and medical marijuana providers who are acting in accordance with state laws.
Currently, a bipartisan, liberal-libertarian coalition in Congress is backing legislation that would amend the federal Controlled Substances Act so that anyone acting in compliance with a state marijuana legalization or medical marijuana law would be immune from federal criminal prosecution. There are a few companies that are taking a leadership role in helping to bring reforms,standardization and transparency to this controversial and fast growing industry. When and if federal legalization occurs, there will be great opportunities in developing cannabis related medical applications.
All Copyrights Trademarks and/or their respective Domains are owned by AlleyBioSystems,LLC , All rights reserved 2013